Calidi Biotherapeutics has demonstrated excellent safety results and preliminary indications of efficacy in a 25 patient late-stage, metastatic cancer phase 1 study combining stem cells with oncolytic viruses.

We are currently working with the Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence a new Phase 1b/2a clinical trial for our leading product candidate.  Therapies initially under development are for prostate cancer, triple-negative breast cancer, and melanoma.

Looking beyond our first product, Calidi‘s proprietary engineered oncolytic viruses can be selectively programmed in a variety of ways, including i) imaging to diagnose cancer, ii) delivering additional therapeutic agents, and iii) targeting cancer stem cells responsible for the cancer recurrence. There are multiple product lines in development to deliver a diverse range of anti-cancer and immunomodulatory agents.